Morepen Laboratories Ltd
Morepen Laboratories Ltd (MOREPENLAB) last reported results for the quarter ended Jun 2026, with sales of ₹570 crore and net profit of ₹56 crore. The stock last traded at ₹130, a market capitalisation of ₹7,096 crore, on a P/E of 60.4. Over the past 52 weeks the stock has ranged between ₹33 and ₹151. Figures are as of 9 Oct 2026 and are not real time.
Morepen Laboratories Ltd share price and key metrics
- Current price
- ₹130
- Market cap
- ₹7,096 cr
- Stock P/E
- 60.4
- Book value
- ₹22.8
- ROE
- 5.33%
- ROCE
- 8.05%
- Dividend yield
- 0.15%
- 52w high / low
- 151/33.0
Metrics as of 9 Oct 2026. Not real time.
Track Morepen Laboratories Ltd
Cruxal reads every Morepen Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Morepen Laboratories Ltd growth and returns
- 10 Years
- 14%
- 5 Years
- 9%
- 3 Years
- 8%
- TTM
- 9%
- 10 Years
- 14%
- 5 Years
- -8%
- 3 Years
- 18%
- TTM
- 27%
- 10 Years
- 19%
- 5 Years
- 18%
- 3 Years
- 54%
- 1 Year
- 170%
- 10 Years
- 12%
- 5 Years
- 10%
- 3 Years
- 9%
- Last Year
- 5%
Morepen Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹570 cr, up 34.1% from ₹425 cr a year earlier. Net profit was ₹56 cr, up 409.1% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 438 | 453 | 466 | 425 | 412 | 484 | 485 | 570 |
| Expenses | 394 | 417 | 424 | 401 | 381 | 438 | 460 | 488 |
| Operating profit | 44 | 36 | 42 | 24 | 31 | 46 | 24 | 83 |
| OPM % | 10% | 8% | 9% | 6% | 7% | 10% | 5% | 14% |
| Other income | 5 | 5 | 5 | 4 | 30 | 4 | 8 | 5 |
| Interest | 1 | 1 | 5 | 4 | 4 | 4 | 4 | 5 |
| Depreciation | 2 | 5 | 16 | 9 | 11 | 10 | 6 | 8 |
| Profit before tax | 46 | 35 | 26 | 16 | 46 | 35 | 23 | 75 |
| Tax % | 24% | 24% | 21% | 26% | 10% | 22% | 33% | 24% |
| Net profit | 35 | 27 | 20 | 11 | 41 | 28 | 16 | 56 |
| EPS (₹) | 0.64 | 0.49 | 0.37 | 0.20 | 0.75 | 0.50 | 0.29 | 1.03 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Morepen Laboratories Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 595 | 607 | 769 | 853 | 1,188 | 1,547 | 1,418 | 1,690 | 1,812 | 1,806 | 1,951 |
| Operating profit | 61 | 65 | 68 | 69 | 119 | 137 | 80 | 159 | 174 | 126 | 184 |
| OPM % | 10% | 11% | 9% | 8% | 10% | 9% | 6% | 9% | 10% | 7% | 9% |
| Net profit | 24 | 30 | 29 | 34 | 97 | 102 | 39 | 97 | 118 | 96 | 141 |
| EPS (₹) | 0.53 | 0.66 | 0.64 | 0.75 | 2.16 | 2.13 | 0.76 | 1.88 | 2.15 | 1.73 | 2.57 |
TTM is the trailing twelve months to the most recent quarter.
Morepen Laboratories Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 90 | 90 | 90 | 90 | 90 | 96 | 102 | 102 | 110 | 110 |
| Reserves | 106 | 136 | 163 | 194 | 335 | 483 | 651 | 745 | 1,047 | 1,137 |
| Borrowings | 169 | 134 | 132 | 133 | 17 | 19 | 25 | 29 | 105 | 208 |
| Other liabilities | 173 | 226 | 230 | 246 | 416 | 473 | 332 | 417 | 517 | 482 |
| Total liabilities | 538 | 586 | 615 | 663 | 858 | 1,070 | 1,110 | 1,293 | 1,778 | 1,936 |
| Fixed assets | 272 | 264 | 236 | 216 | 225 | 252 | 267 | 307 | 489 | 513 |
| CWIP | 0 | 0 | 0 | 0 | 2 | 14 | 17 | 24 | 28 | 22 |
| Investments | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 85 | 124 |
| Other assets | 266 | 321 | 379 | 446 | 631 | 804 | 827 | 960 | 1,176 | 1,277 |
| Total assets | 538 | 586 | 615 | 663 | 858 | 1,070 | 1,110 | 1,293 | 1,778 | 1,936 |
As reported by the company. Total assets equal total liabilities by construction.
Morepen Laboratories Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 41 | 63 | 17 | 11 | 51 | -60 | -91 | 73 | 32 | 33 |
| Cash from investing | -14 | -27 | -13 | -12 | -70 | -32 | -47 | -83 | -322 | -126 |
| Cash from financing | -24 | -38 | -0 | 5 | 47 | 66 | 144 | 5 | 300 | 97 |
| Net cash flow | 3 | -1 | 4 | 4 | 28 | -26 | 6 | -5 | 10 | 4 |
| Free cash flow | 31 | 37 | 6 | -6 | 10 | -127 | -137 | -8 | -182 | -127 |
| CFO / operating profit | 66% | 98% | 26% | 25% | 44% | -26% | -94% | 70% | 40% | 46% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Morepen Laboratories Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 9% | 9% | 8% | 10% | 23% | 23% | 8% | 17% | 15% | 8% |
| Debtor days | 57 | 73 | 64 | 59 | 56 | 59 | 68 | 70 | 65 | 67 |
| Inventory days | 65 | 76 | 69 | 91 | 82 | 96 | 87 | 85 | 94 | 88 |
| Days payable | 125 | 173 | 124 | 113 | 98 | 90 | 87 | 101 | 114 | 103 |
| Cash conversion cycle | -3 | -24 | 9 | 37 | 40 | 65 | 69 | 54 | 45 | 53 |
| Working capital days | -86 | -62 | -34 | -8 | 17 | 55 | 98 | 94 | 107 | 118 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Morepen Laboratories Ltd shareholding pattern
Promoters held 35.66% at Sep 2026, broadly unchanged since Sep 2025. FIIs 3.43% and DIIs 1.70%.
| % held | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 35.66% | 35.66% | 35.66% | 35.66% | 35.66% | 35.66% | 35.66% | 35.66% |
| FIIs | 2.22% | 1.94% | 1.72% | 1.62% | 1.62% | 1.59% | 1.46% | 3.43% |
| DIIs | 1.64% | 1.67% | 1.50% | 1.49% | 1.25% | 1.25% | 1.28% | 1.70% |
| Government | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public | 60.46% | 60.72% | 61.09% | 61.22% | 61.46% | 61.50% | 61.59% | 59.19% |
| No. of shareholders | 4,48,361 | 4,68,860 | 4,61,180 | 4,61,853 | 4,53,137 | 4,47,286 | 4,34,912 | 4,03,932 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Cruxal coverage of Morepen Laboratories Ltd
Morepen Laboratories Ltd corporate filings
- Closure of Trading Window for the quarter ended 30 September 2026Insider Trading / SASTlow impact
- Morepen Laboratories releases revised press release under Regulation 30Company Updatelow impact
Cruxal's analysis: Morepen Laboratories has filed a revised press release under Regulation 30 of the SEBI…
Read the full analysis - Morepen Laboratories Limited Announces AGM Voting Results, Approves Dividend and Extension of Medical Devices Business Hive-offAGM/EGMmedium impact
Cruxal's analysis: Morepen Laboratories Limited has successfully concluded its 41st Annual General Meeting…
Read the full analysis - Morepen Laboratories Limited Concludes 41st AGM; Approves Final Dividend and Strategic Restructuring of Medical Devices BusinessAGM/EGMmedium impact
Cruxal's analysis: Morepen Laboratories Limited has concluded its 41st Annual General Meeting, where…
Read the full analysis - Morepen Laboratories Ltd files intimation regarding ESG ratingCompany Updatelow impact
Cruxal's analysis: Morepen Laboratories Ltd has submitted a formal intimation to the stock exchange…
Read the full analysis - Morepen Laboratories completes first phase of manufacturing capacity expansion ahead of scheduleCompany Updatemedium impact
Cruxal's analysis: Morepen Laboratories has announced the successful completion of the first phase of its…
Read the full analysis - Morepen Laboratories Limited announces dispatch of 41st Annual General Meeting notice and Annual Report for FY 2025-26Company Updatelow impact
Cruxal's analysis: Morepen Laboratories Limited has formally announced the completion of the dispatch of its…
Read the full analysis - Morepen Laboratories Ltd issues notice for Annual Report 2025-26Company Updatelow impact
Cruxal's analysis: Morepen Laboratories has issued a specimen letter to shareholders who have not registered…
Read the full analysis - Morepen Laboratories Ltd files Business Responsibility and Sustainability Report (BRSR) for FY2026Otherslow impact
Cruxal's analysis: Morepen Laboratories has submitted its Business Responsibility and Sustainability Report…
Read the full analysis - Morepen Laboratories announces 41st AGM, leadership elevation, and extension of Medical Devices business hive-offAGM/EGMhigh impact
Cruxal's analysis: Morepen Laboratories Limited has scheduled its 41st Annual General Meeting for September…
Read the full analysis - Morepen Laboratories Secures Landmark 825 Crore Multi-Year CDMO ContractOthershigh impact
Cruxal's analysis: Morepen Laboratories has secured a significant multi-year Contract Development and…
Read the full analysis - Morepen Laboratories Announces 41st AGM, Dividend, and Record Date for September 2026Company Updatelow impact
Cruxal's analysis: Morepen Laboratories Limited has formally notified the stock exchanges regarding its 41st…
Read the full analysis - Morepen Laboratories infuses INR 20 crore into wholly owned subsidiary Morepen RX Limited via rights issueCompany Updatelow impact
Cruxal's analysis: Morepen Laboratories Limited has subscribed to a rights issue of its wholly owned…
Read the full analysis - Morepen Laboratories reports strong Q1 FY27 performance with 14% OPM and 56 crore net profitCompany Updatehigh impact
Cruxal's analysis: Morepen Laboratories Limited has reported robust financial results for the quarter ended…
Read the full analysis - Morepen Laboratories files routine monitoring agency report for quarter ended June 30, 2026Company Updatelow impact
Cruxal's analysis: Morepen Laboratories Ltd has submitted its monitoring agency report for the quarter ended…
Read the full analysis - Morepen Laboratories Ltd schedules 41st Annual General Meeting for September 26, 2026Company Updatelow impact
Cruxal's analysis: Morepen Laboratories Ltd (500288) has formally intimated that its 41st Annual General…
Read the full analysis - Morepen Laboratories Reports Stellar Q1 FY2027 Results with 34% YoY Revenue Growth and 394% YoY Net Profit Surge; Sets Dividend Record DateCompany Updatehigh impact
Cruxal's analysis: Morepen Laboratories Limited announced exceptionally strong consolidated financial…
Read the full analysis - Intimation Of Record Date For Payment Of Final Dividend I.E. September 19, 2026Corp. Actionmedium impact
- Morepen Laboratories files press release under Regulation 30 (LODR)Company Updatelow impact
Cruxal's analysis: Morepen Laboratories Ltd. announced on 2026-08-04 that it has filed a press release/media…
Read the full analysis - Morepen Laboratories Reports Record Q1 FY27 Performance with 394% PAT Growth, Driven by CDMO and API Business ExpansionCompany Updatehigh impact
Cruxal's analysis: Morepen Laboratories Limited has announced an exceptionally strong Q1 FY27, reporting its…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.